April 24, 2023—Ichor Vascular Inc announced that the company has received European patent approval from the European Patent Office (EPO) for its arterial and venous solutions to treat peripheral vascular occlusions.
According to Ichor Vascular, the patent approval strengthens the company’s patented portfolio that includes intellectual property in the United States and Canada, as well as in the European Union.
Tim Blair, CEO of Ichor Vascular, commented in the company’s press release, “Patent expansion has been a pragmatic and strategic component of our strategy from inception with plenty of roadblocks and challenges along the way. The EPO granting patents to our applications is a lengthy and sophisticated process and something we will certainly celebrate.”
Ichor Vascular’s peripheral Ichor reperfusion system has received FDA 510(k) clearance for clot removal in lower-extremity vascular disease. A company-sponsored article, “The ICHOR Reperfusion System for Clot Removal in Lower Extremity Vascular Disease,” showcasing the technology was published in Endovascular Today in February 2022.
In March 2023, the company announced the submission of a 510(k) application with the FDA for its venous peripheral reperfusion system.
The Ichor Vascular system is designed to be an intuitive, first-line treatment in the peripheral thrombectomy toolbox. Postmarket data will focus on improved time to reperfusion, reductions in blood loss compared to vacuum-pump based systems, reductions in distal embolization, minimizing vessel and valve damage, and reducing or eliminating surgical and drug complications with its straightforward endovascular approach, stated the company.
About iCHOR
iCHOR was founded by Interventional Radiologist Dr. Troy Long and industry veteran Tim Blair. They identified an opportunity to develop new technologies to address these large unmet needs in treating peripheral vascular occlusions. This collaboration has lead to the development of the iSWEEP platform technology that has converted the tried and true Fogarty balloon sweep technique from an open surgery to a simple, minimally-invasive endovascular procedure.
For further information please contact:
Tim Blair
Chief Executive Officer
[email protected]
